
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Indus is expected to experience continued growth under strong leadership, with a focus on branded drugs and a diverse pipeline. The company's recent shift to branded drugs has led to improved revenue and credit rating, and potential M&A opportunities could further bolster growth. The launch of their new drug, UZEDY, for nervous system disorders and expansion into international markets show promising potential for the company's growth in the long-term.
Bears say
Teva Pharmaceutical Indus is facing a multitude of challenges that may hinder its growth, such as high debt levels, declining sales for its major drug Copaxone, increased competition in the generic drug market, and ongoing legal issues surrounding opioid sales. Additionally, the company's acquisition of Allergan's generics business has not met expectations, resulting in a write-down of $1.6 billion. All of these factors contribute to a negative outlook for TEVA's stock.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares